How do you take cardarine?

Doses, schedule and length in the human trials
TrialDose and schedulePeopleLength
PAD20001 report, January 200812.5, 5 or 10 mg once daily by mouth, or placebo283 randomized (84 placebo, 50 at 2.5 mg, 86 at 5 mg, 63 at 10 mg), aged 18 to 75 with low HDLc12 weeks
Olson et al., 201232.5, 5.0 or 10.0 mg, or placebo; a sequence of 5 and 10 mg in the second study268 with HDL cholesterol <1.16 mmol/L, plus 37 in a second, smaller exploratory study12 weeks (main study)
Sprecher et al., 200742.5 mg or 10 mg, orally, once-daily, or placeboHealthy volunteers, hospitalized and sedentary: 6 on placebo, 9 on 2.5 mg, 9 on 10 mg2 weeks
Risérus et al., 2008510 mg o.d., against a PPARalpha agonist (GW590735) and placebosix healthy moderately overweight subjects per group2 weeks
Ooi et al., 201162.5 mg/d or placebo, crossover13 dyslipidemic men with central obesity6-week periods, 2-week placebo washout

In human trials cardarine (GW501516) was given by mouth as 2.5, 5 or 10 mg once daily, for up to 12 weeks.12

Doses, schedule and length in the human trials

The table is set at the top of the page

The registry entry NCT00158899, the PAD20001 report and Olson et al. (2012) each describe 12 weeks of 2.5, 5 or 10 mg in people with low HDL cholesterol, and give different numbers: 424 enrolled in the registry,2 283 randomized and 290 in the safety population in the report,1 and 268 plus 37 in the paper.3 In PAD20001, participants were given two bottles of blinded study medication and instructed to take by mouth 1 tablet in the morning from each bottle.1 It lists each dose as once daily, with 2.5 mg in Stage 1 only and 10 mg in Stage 2 only.1 The trials did not define a cycle.

Liquids, drops and storage

The registry entry for GlaxoSmithKline's 12-week trial, NCT00158899, lists the study drug as GW501516 oral tablets, and searches of DailyMed, ClinicalTrials.gov and PubMed found no liquid, drops or mL dose.2 DailyMed and the trial registry list no label with tablet, capsule or powder strengths; only the trial tablets (2.5, 5, 10 mg) are recorded.2 The same searches, with regulator pages, found no storage condition before or after mixing.

Approval, results and safety

USADA says GW1516 is not available anywhere as an approved medication and has no recognized therapeutic uses.7 It also says GW1516 was pulled from clinical trials when it caused cancer, a finding it places in animals given large doses.7 An FDA warning letter of December 12, 2025 to one seller, Dynamic Health Group dba SARMS AMERICA, says the products it offered as SARMs, including Cardarine GW501516, are unapproved new drugs.8

In PAD20001 the largest HDL cholesterol rise over placebo at week 12, 13.3% (95% CI: 7.6, 18.9), was in the 10 mg group, with 9.3% at 2.5 mg and 8.1% at 5 mg.1 Olson et al. (2012), reporting changes from baseline, give HDL cholesterol increases up to 16.9% at 10 mg.3 The report records a dose-related increase in weight, with the difference from placebo at week 12 statistically significant for the 10 mg group, 1.74kg (95% CI: 0.70, 2.78).1 The report says the long-term clinical relevance of its findings is difficult to ascertain.1

Frequently asked questions

Does any human trial of cardarine use a dose above 10 mg?

Not in the trials found, which gave 2.5, 5 or 10 mg;13456 the 20 in one 2008 study is a dose of a comparator drug, GW590735, not of cardarine.5

Does WADA prohibit cardarine?

The WADA 2026 Prohibited List, in effect from 1 January 2026, names GW1516 and GW501516 as examples of PPARδ agonists under S4.4 metabolic modulators.9

Is cardarine on the Australian Register of Therapeutic Goods?

Sport Integrity Australia says GW1516 is not on the register, and that the TGA lists it under Schedule 10.10

References

  1. EU Clinical Trials Register (sponsor report). gsk-pad20001-synopsis-redact. clinicaltrialsregister.eu
  2. ClinicalTrials.gov. NCT00158899: GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol. 2006. clinicaltrials.gov
  3. PubMed. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. 2012. pubmed.ncbi.nlm.nih.gov
  4. PubMed. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. 2007. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. 2008. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. 2011. pubmed.ncbi.nlm.nih.gov
  7. USADA. What Should Tested Athletes Know About GW1516? | USADA. usada.org
  8. FDA. Dynamic Health Group dba SARMS AMERICA - 719257 - 12/12/2025. fda.gov
  9. WADA. WORLD ANTI-DOPING CODE. wada-ama.org
  10. Sport Integrity Australia. GW1516 (GW501516) Information | Sport Integrity Australia. sportintegrity.gov.au